Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 31;134(18):1558-1561.
doi: 10.1182/blood.2019001728.

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Gunnar Juliusson  1   2 , Oskar Hagberg  3 , Vladimir Lj Lazarevic  1 , Emma Ölander  4 , Petar Antunovic  5 , Jörg Cammenga  6 , Lovisa Wennström  7 , Lars Möllgård  7 , Mats Brune  7 , Martin Jädersten  8 , Stefan Deneberg  8 , Sören Lehmann  8   9 , Åsa Rangert Derolf  8 , Martin Höglund  9   10
Affiliations

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Gunnar Juliusson et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Overall survival (OS) of AML (non–acute promyelocytic leukemia [APL]) by time period, age at diagnosis, and sex. Age <50 years (n = 825, P = .67) (A); age 50 to 59 years (n = 805, P = .003) (B); age 60 to 75 years (n = 2708, P = .00002) (C); age >75 years (n = 2657, P = .50) (D); women age 50 to 75 years (n = 1564, P = .69) (E); and men age 50 to 75 years (n = 1949, P < .00001) (F). Lines represent the 4 time periods, distinguished by their length of follow-up.
See this image and copyright information in PMC

References

    1. Foreman KJ, Marquez N, Dolgert A, et al. . Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-2090. - PMC - PubMed
    1. Yates JW, Wallace HJ Jr., Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485-488. - PubMed
    1. Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017;130(23):2469-2474. - PubMed
    1. Juliusson G, Antunovic P, Derolf A, et al. . Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-4187. - PubMed
    1. Bower H, Andersson TML, Björkholm M, Dickman PW, Lambert PC, Derolf Å. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6(2):e390. - PMC - PubMed

Publication types